Developing breakthrough treatments for fibrotic diseases


Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant’s mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design.


Year Invested: 2016
Location: Redwood, Calif.
Visit: www.pliantrx.com

Recent News

February 13, 2019
Pliant Therapeutics to Present at Upcoming Investor Conferences

January 3, 2019
Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809; Development in Orphan Lung Disease Idiopathic Pulmonary Fibrosis Planned

January 3, 2019
Pliant Therapeutics Appoints Keith Cummings as Chief Financial Officer and Eduard Gorina as Vice President, Clinical Development

Read More News

Associated Team Members

Neil Exter
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner